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57 ABSTRACT 
The invention provides a means for attaching a label, 
support or bioactive agent to a protein with an exopep 
tidase at a site that is remote from the active site of the 
protein. More specifically the invention is directed to a 
method for the attachment of an amino acid, amine and 
alcohol nucleophile to the carboxyl terminus of a pro 
tein. In one embodiment, a labeled nucleophile is at 
tached to a protein such as an antibody. In other em 
bodiments, the invention is directed to a method for the 
attachment of a protein to an immobilization support 
and to a method for the attachment of a bioactive agent to a protein. 
40 Claims, 2 Drawing Sheets 
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EXOPEPTIDASE CATALYZED SITE-SPECIFIC 
BONDING OF SUPPORTS, LABELS AND 
BOACTIVE AGENTS TO PROTEINS 
TECHNICAL FIELD 
This invention relates to immobilized and labeled 
proteins and to the attachment of proteins to bioactive 
agents. Specifically, it relates to methods for attaching 
labels, immobilization supports and bioactive agents to 
specific sites of proteins. 
BACKGROUND OF THE INVENTION 
It is well-known that the function of bioactive prote 
ins can often be enhanced by their combination with 
other substances. When used to catalyze a reaction or to 
obtain separation, proteins can be immobilized to in 
crease reaction efficiency and simplify the processing. 
When used as detecting agents, proteins can be labeled 
to facilitate measurement. When used to complex with 
or treat biological organisms, proteins can be combined 
with bioactive agents (hereinafter called "augmenta 
tion") to help achieve treatment efficacy. 
Methods for immobilizing proteins are desirable be 
cause they localize reaction sites and improve economic 
recovery. Moreover, immobilized proteins are gener 
ally less susceptible to the loss of activity due to chemi 
cal attack and changes in temperature and pH than are 
free proteins. 
Methods for labeling or augmenting proteins are 
desirable because they facilitate quantification, localiza 
tion, specificity and reactivity of the protein. The result 
ing combinations, moreover, are the resulting combina 
tions and/or powerful tools for clinical analysis and 
treatent. 
Numerous techniques exist for protein immobiliza 
tion on solid supports. Proteins can be physically ad 
sorbed onto inert supports or can be covalently bound 
to the support through reaction with bifunctional linker 
arms. Microencapsulation, gel entrapment and com 
plexation (with ion exchange resins) also can bind and 
immobilize. 
Numerous techniques also exist for binding labels and 
bioactive agents to proteins. Most of these techniques 
call for reaction of the label or agent and a functional 
group of the protein, such as an amino group, which 
occurs repeatedly throughout the protein. Although 
some repetitions of such a group are shielded from 
binding by the conformation of the protein, many others 
are exposed and available for binding with the labeling 
group or bioactive agent. The result is a mixture of 
proteins having labels or bioactive agents attached at 
various non-specific sites. 
With any of these techniques for immobilizing, label 
ing or augmenting, several criteria should be met. The 
first is a correct spatial orientation for optimum reactiv 
ity of the proteins. A protein functions best when it is 
bound in a fashion that orients its active sites away from 
the support, label or bioactive agent and renders the 
sites available for functional operation. The second is 
the exhibition of protein activities and specificities that 
are at least comparable to those exhibited by the un 
bound form of the protein. The third, which is espe 
cially applicable to immobilization, is the capability for 
repeated use and for a high packing density. The fourth 
is the avoidance of attachment of the support, label or 
agent within or in the vicinity of the active site of the 
protein. Otherwise, the resulting loss of functional ca 
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pacity often causes inadequate reactivity and the need 
to use more protein. 
One of the most important protein embodiments 
being investigated today is the antibody. The need to 
minimize the attachment of immobilizing supports, la 
beling groups or bioactive agents within or near the 
antigen-binding site of an antibody is widely recog 
nized. 
One method for such minimization involves binding 
antigen to the antibody prior to reaction with the label 
ing group, bioactive agent, or immobilizing support. In 
this manner, the antigen shields the antibody binding 
site from reaction. The success of this shielding method, 
however, is limited. Although a high affinity of the 
antibody for the antigen exists, the equilibrium between 
the antibody/antigen complex and the free an 
tibody/antigen enables free antibody to react. This has 
foreseeable negative consequences. In addition, expo 
sure of the antigen to a labeling group, bioactive agent, 
or immobilizing support often results in attachment of 
that material to the antigen. 
The known methods for immobilizing, labeling or 
augmenting any kind of protein fall far short of main 
taining the functional capacity of the protein. Protein 
reactivity is generally lessened. Proper spatial orienta 
tion and packing density are often lacking. And, as a 
result, many attendant economic, toxic, reactive and 
non-specificity problems occur. Consequently, better 
and more specific methods for binding labels, supports 
or bioactive agents to proteins are needed. 
It is an object of the invention, therefore, to develop 
methods for labeling, immobilizing or bioactively aug 
menting proteins at sites remote from the functionally 
active site or sites of the protein. It is also an object of 
the invention to immobilize proteins by covalently bind 
ing them to an inert immobilization support. Another 
object of the invention is to covalently bind a label to a 
specific site of a protein. Another object is to covalently 
bind bioactive agents to a specific location on a protein. 
A further object of the invention is to immobilize prote 
ins so that they have the correct spatial orientation and 
packing density which will allow unhindered access to 
the functionally active site. 
SUMMARY OF THE INVENTION 
These and other objects are achieved by the present 
invention which is directed to methods for immobiliz 
ing, labeling and augmenting proteins. Generally, the 
method involves binding the immobilization support, 
label or bioactive agent (hereinafter called "auxiliary 
substance') to a protein at a specific site so that interfer 
ence with the function and performance of the protein is 
minimized or eliminated. Preferably, this specific site is 
highly remote from the active sites of the protein. 
In particular, the method of the invention involves 
two primary reactions. The first (hereinafter called the 
"primary coupling reaction"), catalytically couples an 
amino acid, an amine or an alcohol (hereinafter called 
"nucleophile"), to the carboxy terminus of the protein 
through the use of an exopeptidase enzyme. The second 
(hereinafter called the "primary binding reaction"), 
binds the side chain of the nucleophile to a specifically 
reactive group attached to the auxiliary substance. 
The method of the invention can be practiced by 
alternative synthetic routes depending on whether the 
primary coupling reaction or primary binding reaction 
is conducted first. These two routes are depicted in the 
5,279,954 3 
scheme presented in the following section entitled De 
tailed Description of the Invention. 
The first synthetic route can be employed with all 
sizes and solubilities of reactants. A nucleophile having 
a distinctive side chain is first coupled to the carboxy 
terminus of the protein by the primary coupling reac 
tion. This coupling either adds the nucleophile to the 
carboxy terminus of the protein (condensation) or sub 
stitutes the nucleophile for the amino acid residue form 
ing that carboxy terminus (transpeptidation with amino 
acid or amine or transesterification with alcohol). The 
resulting protein-nucleophile adduct is then bound to 
auxiliary substance by the primary binding reaction 
which takes advantage of the distinctive character of 
the side chain. The adduct either is directly bound to 
the auxiliary substance or is indirectly bound through a 
bifunctional linker arm. In either case, the binding reac 
tion occurs between the side chain of the nucleophile 
and a specifically reactive group on the auxiliary sub 
stance or linker arm. 
The second synthetic route can be employed when 
the molarities of the reactants in the reaction medium 
are sufficient to permit relatively rapid enzymatic cou 
pling. A nucleophile is first bound to the auxiliary sub 
stance by the primary binding reaction to form an inter 
mediate of auxiliary substance and nucleophile. The 
binding can be accomplished by direct reaction of the 
side chain of the nucleophile and the auxiliary substance 
or indirectly through a linker arm that has been pre 
bound to the auxiliary substance. The intermediate is 
then coupled to the carboxy terminus of the protein by 
the primary coupling reaction. Transpeptidation, con 
densation and transesterification with amino acid, amine 
or alcohol nucleophiles can all be employed in this 
primary coupling reaction. 
The proteins used in the method of the invention are 
biologically-active polypeptides. Included without limi 
tation are enzymes, enzyme inhibitors, peptide hor 
mones, DNA binding proteins, reading frame proteins, 
transcriptases, antibodies, Fab truncated antibodies, reg 
ulating proteins, peptides as small as two residues and 
various other functional proteins. 
The preferred proteins for use in the inventive 
method are monoclonal or polyclonal antibodies. Pre 
ferred classes of antibodies include those that function 
to detect antigens in biological systems or contaminants 
in biological or inanimate systems, to carry bioactive 
agents to specific sites, to diagnose disease and organic 
disfunction, to separate antigens from other materials in 
biological or inanimate systems, and to remove antigens 
from biological or inanimate systems. Especially pre 
ferred embodiments are mammalian immunoglobulin 
proteins from the IgA, Igld, IgE, IgM, or IgG class of immunoproteins. 
The amino acid nucleophile used in the method of the 
invention is an alpha amino acid having a side chain 
with a reactive substituent. Alternatively, it may have a 
simple, nonfunctional side chain in circumstances where 
it is also the auxiliary substance. When the first syn 
thetic route is employed, the side chain is chosen so that 
the amino acid nucleophile has a distinctive character 
relative to the amino acids of the protein. With this 
design, the amino acid nucleophile rather than the 
amino acids of the protein is selectively and preferen 
tially reacted with a specifically reactive group of the 
linker arm or auxiliary substance. When the second 
synthetic route is employed, such a distinctive character 
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can be used but is not necessary because the primary 
coupling reaction provides the selectivity desired. 
The amine nucleophile used in the method of the 
invention mimics the amino acid nucleophile It is a C2 to 
C20 aliphatic, aromatic or arylaliphatic primary amine 
having a reactive substituent along its backbone or at its 
other terminus. The foregoing conditions regarding the 
character of the amino acid side chain also apply when 
an amine is employed in the first and second synthetic 
Outes. 
The alcohol nucleophile used in the method of the 
invention is an aliphatic, aromatic or arylaliphatic C1 to 
C20 primary alcohol having a reactive substituent along 
its backbone or at its other terminus. 
The linker arm used in the method of the invention is 
a flexible or semi-flexible chain which has as its termini 
(l) a specifically reactive group that is reactive with the 
side chain of the nucleophile and (2) an other functional 
group that reacts with a combining group of the auxil 
iary substance. 
Immobilizing supports useful in the present invention 
are inorganic or organic materials which may be func 
tionalized with a specifically reactive group for selec 
tive reaction with the side chain of the nucleophile, or 
with a combining group that reacts with the other func 
tional group of the linker arm. The support is a porous 
or semiporous material that is biologically inert and 
insoluble in the medium used. 
Bioactive agents include those that act to provide a 
desirable biochemical or therapeutic result. They may 
be functionalized with a specifically reactive group for 
reaction with the side chain of the nucleophile, or with 
a combining group that reacts with the other functional 
group of the linker arm. Included are chemotherapeutic 
agents, oxidizing or reducing agents, cytotoxic agents, 
anticancer agents, radioactive agents, antibiotics, an 
timicotics, anti-infectives, heavy metal agents, antiviral 
agents, lysing agents, chelating groups and the like. 
Labels useful in the present invention include fluores 
cent groups, phosphorescent groups, colorimetric 
groups, radioactive groups, luminescent groups, spec 
trometric groups nuclear magnetic resonance groups, 
electron spin resonance groups and other groups with 
physiochemical properties that may be detected by 
measuring means. These labels may be functionalized 
with a specifically reactive group for reaction with the 
side chain of the nucleophile, or with a combining 
group that is reactive toward the other functional group 
of the linker arm. The nucleophile may also function as 
a label when it carries radioactive atoms. 
The enzymes that carry out the primary coupling 
reactions are exopeptidases. They act specifically at the 
C-terminal end of peptide chains to form or transform 
peptide bonds under basic conditions (condensation and 
transpeptidation) or acidic conditions (transesterifica 
tion) and are relatively stable under the reaction condi 
tions used. 
Preferred groups of exopeptidases for the method of 
the invention are serine carboxypeptidases. Certain of 
these enzymes, known as carboxypeptidase Y, are spe 
cific for amino acids, or amines with neutral or basic 
side chains. Certain other classes of carboxypeptidase 
enzymes are specific for amino acids with acidic side 
chains. Correlation of the exopeptidase enzyme speci 
ficity and the neutral, acidic or basic character of the 
nucleophile to be coupled to the protein is appropriate 
according to the method of the invention. 
5,279,954 5 
The conditions for the enzymatically catalyzed reac 
tion between the protein and the nucleophile include 
control of pH, temperature, concentration and incuba 
tion time. 
The present invention is also directed to methods 
which employ the labeled, immobilized or augmented . protein. 
The method for use of the labeled protein involves 
combining of the labeled protein and the material upon 
which it is to act, removing any excess labeled protein 
and measuring the amount of labeled protein that has 
interacted with the material. In particular, this method 
is useful for detection of antigens or enzymatic sub 
strates/inhibitors by antibodies or enzymes, respec 
tively. 
The method for use of immobilized protein proceeds 
in a known manner as indicated by the character of the 
protein. The protein preferably is an enzyme, antibody, 
DNA binding protein or regulatory protein. The pre 
ferred uses will include enzymatically catalyzed reac 
tions, antibody-antigen complexations, regulation of 
reactions and DNA or enzyme separations and/or puri 
fications. One advantage of this method is the increased 
efficiency and ease of removal of the immobilized pro 
tein due to the immobilization at a specific and constant 
site remote from the reactive sites. Another advantage 
is the ability to increase the packing density of the im 
mobilized protein when all molecules are aligned in the 
same direction and have exposed active sites. 
The method for use of a bioactive agent bound to a 
protein also proceeds in a recognized manner as indi 
cated by the bioactive agent and the nature of the pro 
tein. The action of the protein and bioactive agent coop 
erate to cause the effect desired. The protein may act as 
a carrier to transport the agent across membranes or to 
cause its absorption into fluids, media or cells. It may 
also act as an absorption inhibitor to prevent transport 
of the agent across membranes or to prevent its absorp 
tion into fluids, media or cells. It may further act as a 
targeting vehicle to direct the agent to selective tissue 
sites or receptors. The advantage of this method is that 
by leaving the active sites free, the reaction efficiency 
and tissue selection are increased. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1A is a graph of the pH dependence of the 
incorporation of serine in an antibody with respect to 
time at 0° C. 
FIG. 1B is a graph of the pH dependence of the in 
corporation of serine in an antibody with respect to time 
at 25 C. a. 
FIG. 1C is a graph of the pH dependence of the 
incorporation of serine in an antibody with respect to 
time at 37 C. 
10 
15 
20 
25 
30 
35 
45 
50 
6 
FIG. 2 is a graphical representation of the effect of 
incubation time on serine incorporation. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Until the present invention, a general method for 
highly selective, single site attachment of a auxiliary 
substance to a protein did not exist. The present meth 
ods solve this problem by providing precise control of 
the protein site to which the auxiliary substance is 
bound. This control causes the auxiliary substance to 
bind to a specific site on the protein that is as distant 
from the protein functional sites as possible, i.e. the 
carboxyl terminus, 
More specifically, the present invention is based upon 
the discovery that amino acids, amines and alcohols can 
be coupled to the carboxyl termini of biologically active 
proteins by a condensation or transpeptidation reaction 
under basic, exopeptidase catalysis conditions or by a 
transesterification reaction under acidic exopeptidase 
catalysis conditions (the primary coupling reaction). 
See J.S. Fruton in "Advances in Enzymology", A. 
Meister, ed. Vol. 53, 1982, John Wiley & Sons New 
York, pp. 239-306 for a general review of proteinase 
catalyzed synthesis of peptide bonds, the disclosure of 
which is incorporated herein by reference. With respect 
to almost all functional proteins, and especially antibod 
ies, the carboxyl terminus of the peptide chain or chains 
occurs within a region of its three dimensional structure 
that is almost always remote from the active site region. 
In antibodies, for example, this terminus occurs within 
the constant region that is remote from the active, vari 
able region of the antibody. Consequently, binding the 
auxiliary substance to the carboxy terminus of the pro 
tein provides the control sought. 
As described in the foregoing Summary of the Inven 
tion, the attached substance is bound to the carboxy 
terminus of the protein through either of two synthetic 
routes. In the first, the nucleophile is separately coupled 
to the protein to form an adduct of the protein and 
nucleophile. The adduct is then bound to the auxiliary 
substance directly, or is bound indirectly through a 
linker arm-auxiliary substance combination. 
In the second synthetic route, the nucleophile and 
auxiliary substance are directly bound, or indirectly 
bound through a linker arm, to form an intermediate. 
The intermediate is then coupled to the carboxy termi 
nus of the protein. 
These synthetic routes are depicted in the following 
scheme. Both synthetic routes operate in two versions, 
which depend upon whether the auxiliary substance is 
directly or indirectly bound to the nucleophile. 
Schene 
Route 1 
ProCO2H (protein) 
-- 
X-R (nucleophile) 
with enzyme . 
5,279,954 
-continued 
Scheme 
ProCOX-R 
-- sRG-ty 
ProCOX-R-SRG-(ASub) ? U 
ProCOX-R-SRG-(Link)-(ASub) 
Route 2 
X-R 
X-R 
-- SRG-(Link)-(ASub) SRG-(ASub) 
X-R-SRG-(Link)-(ASub) 
-- 
ProCO2H 
ProCOX-R-SRG-(Link)-(ASub) 
with enzyme 
\ - SRG-(Link)-(ASub) 
ProCOX-R-SRG-(Link)-(ASub) 
(adduct) 
(nucleophile) 
(protein) 
ProCOH is protein. R-X is the nucleophile. i.e., amino acid or aliphatic amine wherein R is the side chain 
and X is the attaching amine or hydroxy group. ASub is attached substance. Link is a linker arm. SRG is 
specifically reactive group. The letter n is the number 0 and 1. Choice of X, R, SRG and route depend upon 
the functional groups of the protein and the solubilities of the reactants. 
Route 
According to route 1, the first step is the primary 
coupling reaction to form the adduct of protein and 
nucleophile. It is accomplished by exopeptidase cataly 
sis under non-neutral conditions. 
The choice of the particular amino acid, amine or 
alcohol as the nucleophile in the first step depends upon 
the identity of the amino acids of the protein and upon 
the distinctive character of the side chain of the nucleo 
phile. The side chain of the coupled nucleophile acts as 
the binding site for the specifically reactive group of the 
attached substance or the combination of linker arm 
attached substance. It has a structure that either is non 
duplicative of the amino acids of the protein or is more 
highly reactive toward the specifically reactive group 
of the combination or auxiliary substance than are the 
amino acid side chains of the protein. It also is selected 
to avoid or minimize direct reaction with these side 
chains. 
This selectivity imposed by the nucleophile side chain 
is accomplished by its reactive substituent. This substit 
uent may be a sulfhydryl, olefinyl, amino, azidyl, hy 
drazinyl, epoxy, hydroxyl, activated hydroxy wherein 
the activator is a facile leaving group such as tosyl, 
mesyl and benzoyl, an acid group such as carboxyl, 
phosphoric or sulfonic, an activated ester such as a 
mixed anhydride, carbodiimido, iminyl amidinyl, 
imidazo, pivaloyl ester, neopentyl ester and the like, 
phosphoramidoyl, ferrocenyl, ferro complexes, boronyl 
and similar reactive functional groups. 
In the second step of route 1, the primary binding 
reaction is accomplished by binding the nucleophile 
side chain either to the auxiliary substance or to its 
combination with the linker arm. In both of these varia 
tions, the specifically reactive group of the combination 
or auxiliary substance correlates with the reactive sub 
stituent of the side chain so that the side chain and auxil 
iary substance or combination readily react without 
substantially involving other groups of the protein. 
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To accomplish this selective reactivity of the primary 
binding reaction, the reactive substituent and specifi 
cally reactive group are correlated as pairs of groups. 
Several embodiments of this pair exhibit non-competi 
tive binding which essentially will not involve other 
groups of the protein. These include, for example: (l) a sulfhydryl and an organometallic group, prefera. 
bly an organomercuric group or Alman reagent 
which are particularly useful with antibodies be 
cause antibodies do not naturally contain free sulf 
hydryl groups, i.e. cysteine within or close to their 
active sites; 
(2) an olefinyl group and a dienyl group, which form 
a Diels-Alder adduct; (3) a phosphoramidoyl group and a metallophos 
phoramidoyl or metallophosphate group, which 
form co-ordinate complexes; (4) an affinity complexing compound and its corre 
sponding substrate, e.g. carbonic anhydrase and 
sulfanilamide or biotin and avidin, which form 
affinity complexes; 
(5) a ferrocenyl group or ferro complex and a mag 
netic material rendered inert to the reaction me 
dium, e.g. a teflon-coated iron wire coil, which form a magnetic couple; 
(6) a chelating group and a chelated moiety such as 
ethylene diamine tetraacetate and a transition 
metal, which form a chelate; 
(7) a polar olefinic or substituted olefinic group and 
the corresponding monomer, which polymerize by 
acryloyl lysine and acrylamide, and form a poly 
mer; 
(8) a pair of olefinic groups, which can be hy 
droborated and then treated with silver nitrate and 
weak base to form the reduced, coupled olefin-ole 
fin adduct; and 
(9) a photoreactive arylketo group and a free radical 
stabilizing group having a radical-labile C-H 
bond; such as benzoylphenylalanine and a benzyl, 
allyl or arylalkyl group, which can be photolyzed 
5,279,954 
to form an adduct between the keto carbon and the 
C-H carbon of the free radical stabilizing group. 
Preferably such free radical stabilizing groups as 
polyamide, polycinnamide, polystyrene, or fluo 
rene containing polymers (supports), porphyrin or 
fluorescein, (label) and benzyl substituted bioactive 
agents are employed at significantly higher concen 
trations than the protein coupled to the arylketo 
nucleophile so that photolytic addition of the pro 
tein to itself is highly disfavored (See J. C. Kauer, 
et al., J. Biol. Chem, 261, 10695 (1986)). 
Other embodiments of this pair exhibit competitive 
binding relative to the functional groups of the protein 
but can be controlled to provide a substantially selective 
reaction of the side chain and attached substance or 
combination. These include, for example: 
(1) an aromatic amino group and an epoxy, activated 
ester or aldehyde group, preferably an aromatic 
epoxy or aldehyde group, which can be reacted to 
form a nitrogen-carbon adduct, and under slightly 
acidic conditions to protonate the amine groups of 
the protein; 
(2) an azidyl or hydrazinyl group and an aromatic 
amine, which can be reacted by irradiation with 
UV light to form a substituted amine, and under 
slightly acidic conditions to protonate the amine 
groups of the protein; 
(3) an aromatic alcohol (e.g. phenolic group) or aro 
matic amine and an activated ester, which can be 
reacted to form an ester or amide respectively, and 
under slightly acidic conditions to protonate the 
amine groups of the protein; and 
(4) a hydrazine and a reducing sugar, which form an 
OSaZOe. 
The conditions and procedures for performing the 
binding reactions of the side chain and specifically reac 
tive group are known in the art. See for example "Rea 
gents for Organic Synthesis" by Fieser & Fieser, John 
Wiley & Sons, New York, Vol. I-X, 1967-1975 the 
disclosure of which is incorporated herein by reference. 
The conditions will generally be approximately ambient 
temperatures (0 to 38 C.), and dilute to moderate con 
centrations of reactants. The procedures will generally 
involve stirred reactors, removal of side products and 
slow addition of reagents. A further condition is the 
maintenance of a minimal concentration of any reactant 
that can react with more than one group in the reaction 
mixture. For example, a minimum concentration of 
auxiliary substance or combination in the binding reac 
tion is to be maintained so that the chance of undesirable 
side reactions of the specifically reactive group with the 
protein are minimized. wa 
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Route 2 
According to route 2, the nucleophile and the auxil 
iary substance or its combination with linker arm are 
first bound by the primary binding reaction to form an 
intermediate. This step can be accomplished by employ 
ing (1) any of the reactive substituent and specifically 
reactive group pairs described above; (2) the combining 
group and other functional group pairs described below 
for the linker arm, or (3) by any of the known methods 
for forming an amide, ester, ether, imino, carbonate, 
urethane (carbamate), carbon-carbon, carbon-nitrogen, 
sulfur-carbon, sulfur-oxygen-carbon or carbon-oxygen 
bond. Methods to form these bonds and the particular 
groups formed thereby are known in the art. See, for 
example "Chemical Reagents for Protein Modifica 
tion", CRC Press Inc., R. L. Lundblad & C. M. Noyes 
ed. 1984; "Basic Principles of Organic Chemistry", J. D. 
Roberts and M. Caserio, Benjamin Press, 1975, the dis 
closures of which are incorporated herein by reference. 
Choice of the particular manner of binding the auxil 
iary substance or combination to the nucleophile does 
not depend upon the structure of the protein according 
to this route. Any stable binding group that is appropri 
ate for the chemical structures of nucleophile and auxil 
iary substance or linker arm combination will suffice 
because this binding reaction is not conducted in the 
presence of the protein. 
The second step of route 2 couples the intermediate 
to the protein through the primary coupling reaction of 
the nucleophile portion of the intermediate and the 
protein carboxy terminus. It is accomplished by exopep 
tidase catalysis under non-neutral conditions. The selec 
tivity of this reaction suits it as the one to be conducted 
in the presence of protein. The scheme of route 2 uti 
lizes this feature to best advantage because it places the 
primary coupling reaction last in the reaction sequence 
thereby eliminating the potential interference from the 
primary binding reaction. 
The second step of route 2 has some attendant param 
eters that primarily are directed to reaction efficiency. 
The reactants should have sufficient solubility in the 
reaction medium to enable relatively facile coupling to 
take place. Generally, this solubility will be preferably 
about 0.05 to 2M for the reactants and 1 to 100 uM for 
the enzyme. When the solubilities of the reactants of the 
coupling reaction are less than this, route 1 is preferen 
tially employed. 
Specific embodiments of labels, support materials and 
bioactive agents that can be coupled to proteins by 
synthetic route 2 are shown in Table 1. 
TABLE 1 
- Amino Acids for Coupling Labels, Bioactive Agents and Supports to Antibodies 
(Potential Applications are listed along with the chemical names of the Amino Acids) 
HOCH2CH(NH2)CO2H H2NCH2CH2SO3H I(OH)C6H3CH2CH(NH3)CO2H 
Serine Taurine Iodotyrosine 
3H, 14C 3H, 14c, 35s 129, 13] I 
Radioactive Label Radioactive Label Radioactive Label 
H2NCH2CH2PO3H FC6H4CH2CH(NH2)CO2H 
Aminoethanephosphonic Acid Fluorophenylalanine 
3H, 14c, 32P NMR Label 
Radioactive Label 
P. NMR Label 
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TABLE 1-continued 
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Amino Acids for Coupling Labels, Bioactive Agents and Supports to Antibodies (Potential Applications are listed along with the chemical names of the Amino Acids) 
// 
/ N 
C C 
Metal Chelate Platinum for Electron Microscopy and X-ray Labels 
Cobalt for Radiation Therapy 
fluorescenyl NHCSNH(CH2)4CH(NH2)CO2H 
Fluorescent Label 
(NO2)2C6H3NH(CH2)4CH(NH)CO2H Bisnitrophenylysine 
Fluorescent Label 
Antigenic Label 
NH 
N. NH CO1  
Biotin Group for Complex Attachment to Avidin Resin or as 
Label for Enzymatic Detection 
H2C=HCH2NH + CH3CH=CHCH=CHCO2-(attached substance) 
Diels-Alder 
For Attachment of Resin or other attached substance 
H2C=CHCONHCCH2)4CH(NH2)CO2H + H2C=CHCONH-(H or attached substance) 
Free Radical Polymerization 
FCSH-CH3NH- -- 
wire 
Magnetic Process 
Linker Arm 
There are several reasons why the linker arm version 
of routes i and 2 would be selected according to the 
invention. First, the environment of the carboxyl termi 
nus may prevent approach of a large, bulky auxiliary 
substance. Second, the auxiliary substance may not 
contain functional groups that are specifically reactive 
with the side chain of the nucleophile. Third, the linker 
arm increases the distance between the auxiliary sub 
stance and the protein which can help maintain the 
activity of the protein. Fourth, the protein can more 
freely adopt a spatial conformation that is appropriate 
for its reactivity. Fifth, it will lessen or minimize alter 
ation of protein confirmation caused by carrier material proximity. 
The structure of the linker arm includes functional 
groups at the ends of a flexible to semi-flexible chain. 
One of the functional groups is the specifically reactive 
group mentioned above that reacts with the side chain 
of the nucleophile. The other functional group of the 
linker arm is chosen to readily react with available 
combining groups on the auxiliary substance. Of course, 
this pair of groups of the linker arm is selected so that 
one does not substantially interfere with the other they 
are used when in the binding and combining reactions. 
In both synthetic routes, the step to combine linker 
arm and attached substance is accomplished before the 
binding reaction with the nucleophile. Since protein 
and nucleophile are not present during this step, the 
45 
50 
55 
65 
kinds of reactions available are numerous. If the com 
bining group of the auxiliary substance is an aldehyde 
group, the other functional group may be an amine 
(Schiff base product), an activated acid such as an 
iminocarboxy, carboxyalkoxy or acid halide (amide 
product) or epoxy (substituted amine product). If the 
combining group of the auxiliary substance is an hy 
droxy group, the other functional group may be an 
activated acid or ester (ester product) or activated alkyl 
such as a halo alkyl, alkyl tosyl or alkyl mesyl (ester 
product). If the combining group of the auxiliary sub 
stance is an acid group, the other functional group may 
be an amine (amide product) or activated hydroxyl (ester product). If the combining group of the auxiliary 
substance is chelating agent, the other functional group 
may be a bound metal group. Other pairs of reactants 
include water soluble carbodiimide and amino; N-acyl 
succinimide and amino; and olefin and diene as well as 
those described above under part (3) of the primary 
binding reaction for route 2. Of course, the reverse 
order of reaction is also possible. 
The backbone of the linker arm may be any that 
provides a flexible or semi-flexible chain. Included are 
polymers and oligomers of amides (peptides), olefins, 
esters, carbonates, urethanes, ethers, epoxides and the 
like. Also included are alkylene and hydrocarbon 
chains. The length of the backbone may be from about 
two to about 100 atoms or monomeric units, preferably 
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about four to about 20 atoms or monomeric units in 
length. Examples of the backbone include hexylenyl, 
decylenyl, poly(4-aminobutyric acid), poly(glycyl), 
poly(glycyl-alanyl), poly(4-hydroxybutyric acid), poly 
lactones, poly(bisphenol-A-diglycidyl ether) and poly 
acrylamide. 
Proteins 
The types of proteins (including peptides as small as 
two residues) that can be coupled according to the 
present invention are active proteins with polypeptide 
chains containing reactive carboxyl termini. Examples 
of suitable proteins include enzymes, enzyme inhibitors, 
hormones including peptide hormones, antibodies, Fab 
truncated antibodies, functional proteins, transcriptases, 
reading frame proteins, DNA binding proteins and 
other biologically active polypeptides. 
With respect to labeling, monoclonal or polyclonal 
antibodies, DNA binding proteins, enzymes, and read 
ing frame proteins are preferred as proteins. They are 
generally useful in the diagnosis of diseases, disorders, 
or hereditary dysfunctions. The antibodies are also gen 
erally useful in separation techniques and for detection 
of antigenic material. This includes mammalian immu 
noglobulin proteins from the IgA, IgD, IgE, IgM, or 
IgG class of immunoproteins. 
With respect to immobilization, mono or polyclonal 
antibodies and enzymes are preferred as proteins. 
With respect to bioactive agents, mono or polyclonal 
antibodies, peptide hormones, histocompatibility prote 
ins, polypeptide inhibitors, peptide toxins, structural 
proteins (e.g. collagen), globular proteins and fibrous 
proteins are preferred as proteins. 
Nucleophile Chosen as an Amino Acid 
A wide variety of amino acid nucleophiles can be 
used in the present invention. Generally these include 
alpha amino acids with neutral, basic or acidic side 
chains wherein the side chains may contain the reactive 
substituents mentioned above. The choice of amino acid 
for labeling antibodies, binding proteins to immobilizing 
support, or binding bioactive agents to proteins is gener 
ally coordinated with the enzyme and the protein 
chosen. Certain enzymes will couple specific amino 
acids to the carboxyl termini of proteins. For example, 
CPD-Y will generally couple amino acids with neutral 
or basic side chains to antibodies. Certain other en 
zymes, which utilize cysteine and/or serine at their 
enzymatic sites and are derived from plant and micro 
bial sources, will couple amino acids with acidic side 
chains to proteins. 
Furthermore, in order to perform the binding reac 
tion, the amino acid nucleophile will exhibit a distinc 
tive reaction character. This will allow its selective 
binding to the auxiliary substance or its combination 
with linker arm. The distinctive character results from 
the reactive substituent of the side chain of the nucleo 
phile as explained above. This reactive substituent may be a sulfhydryl, hydroxy, activated hydroxyl, phospora 
midoyl, hydrazinyl, amino, azidyl, epoxy, acid, boronyl, 
activated esters, ferrocentyl, ferro complex or olefinyl 
group, mixtures thereof and other functionally reactive 
groups. 
Embodiments of these amino acid nucleophiles in 
clude aliphatic amino acids such as monoamino mono 
carboxylic acids, e.g., glycine, alanine, valine, norva 
line, leucine, isoleucine, and norleucine (useful as radio 
active label); hydroxy amino acids such as serine, threo 
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nine, and homoserine; sulfur-containing amino acids 
such as methionine, cystine, cysteine, and taurine (for 
linker arm or auxiliary substance binding); diamino 
monocarboxylic acids such as orthinine, lysine, and 
arginine (for linker arm or auxiliary substance binding); 
and monoamino dicarboxylic acids such as aspartic acid 
and glutamic acid (for linker arm or auxiliary substance 
binding). Also, aromatic amino acids, such as phenylala 
nine and tyrosine; heterocyclic amino acids, such as 
histidine and tryptophan, and olefinic amino acids such 
as 2-amino-2-vinyl acetic acid (for linker. arm or auxil 
iary substance binding) are included within the group of 
amino acids of the present invention. 
Additional amino acids are those with the C-terminal 
end protected. This includes, for example, amides, ani 
lides, hydrazides, esters, and the like. 
Preferred classes of amino acid nucleophile include 
aliphatic amino acids, hydroxy amino acids, their acti 
vated derivatives, phosphoramidoyl amino acids, sul 
fur-containing amino acids, diamino monocarboxylic 
acids, activated ester amino acids, aromatic amino acids 
and heterocyclic amino acids. Especially preferred em 
bodiments include serine, alanin, phenylalanine, taurine, 
lysine, arginine, 2-aminopenta-4-enoic acid and cyste 
ine. Also included are carboxyl protected amino acids, 
such as amides and esters. 
Nucleophile Chosen as an Amine 
The amine nucleophile includes any C2 to C20 pri 
mary amine that has another reactive substituent along 
its backbone as described above. Alternatively, it may 
have a simple, nonfunctional side chain in circum 
stances where it is also the auxiliary substance. In addi 
tion to being a decarboxy analog of the amino acid 
nucleophile, the amine nucleophile may also have a side 
chain substituted by hydroxyl, sulfhydryl, activated 
hydroxyl, epoxy, amino, azidyl, olefinyl, activated es 
ter, hydrazinyl, phosphoramidoyl, boronyl, iminyl, 
amidinyl, ferrocentyl, ferro complexes or other func 
tionally reactive groups. Alternatively, it may have a 
simple, nonfunctional side chain in circumstances where 
it is also the auxiliary substance. 
Nucleophile Chosen as an Alcohol 
The alcohol nucleophile includes any C to C20 pri 
mary alcohol that has another reactive substituent along 
its backbone. The reactive substituent may be a hy 
droxyl, sulfhydryl, activated hydroxyl, epoxy, amino, 
azidyl, hydrazinyl, olefinyl, activated ester, phosphora 
midoyl, boronyl, iminyl, amidinyl, ferrocentyl, ferro 
complex groups, mixtures thereof or other functionally 
reactive groups. Alternatively, it may have a simple, 
nonfunctional side chain in circumstances where it is 
also the auxiliary substance. 
Labels 
Labels for the proteins according to the present in 
vention include labeled, or tagged amino acids having a 
variety of substituents or atoms that possess properties 
suitable for detection by conventional techniques. Such 
properties include photoaffinity, magnetism, radioactiv 
ity, fluorescence, enzymatic activity, electron dense 
(x-ray), nuclear magnetic resonance, electron spin reso 
nance, antigenicity, and phosphorescence. For example, 
amino acids can be labeled with either 14C or 3H atoms. 
Further, the amino acids may be tagged by known fluo 
rescent dyes, porphyrins, colorimetric dyes, reactive 
groups and antigens or enzymatic substrates that permit 
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spectroscopic, photographic or radiometric detection. 
See E. T. Koh, et al., Biotechniques, 7,596 et seq. (1989); 
S. Borman, "Bioconjugate Chemistry Attracts Grow 
ing Interest" in the May 8, 1989 issue of "Chemical and 
Engineering News" at p. 25 et seq., the disclosures of 
which are incorporated herein by reference. 
Enzymes 
Enzymes capable of coupling the nucleophile to the 
protein are exopeptidases, i.e., enzymes capable of act 
ing specifically at the carboxyl terminal end of peptide 
chains. See J. S. Fruton In "Advances in Enzymology", 
in the chapter entitled Reagents for Protein Modifica 
tion as cited above. They form or transform peptide 
bonds and are relatively stable under the reaction condi 
tions used. 
Carboxypeptidase enzymes are generally known to 
cleave the C-terminal peptide bond in polypeptides. 
They exhibit alternative enzymatic activities that are 
pH-dependent. For example, transpeptidation, transes 
terification and condensation products can be formed 
by the pH dependent action of carboxypeptidase Y. 
Preferred carboxypeptidases according to the inven 
tion include serine and cysteine (eg. hydroxy and thiol) 
carboxypeptidases. Certain of the serine and cysteine 
enzymes are capable of attaching amino acids and ali 
phatic amines with neutral or basic side chains to the 
carboxy termini of proteins. Examples of these enzymes 
include carboxypeptidase Y (CPD-Y), penicillocarbox 
ypeptidase S-1 and S-2, carboxypeptidase C and CN, 
malt carboxypeptidase I and II, phaseolin; and carboxy 
peptidase A, carboxypeptidase B and metalloproteases, 
which perform the condensation reaction only. Certain 
other of the serine carboxypeptidase enzymes are capa 
ble of attaching amino acids and aliphatic amines having 
acidic side chains to the carboxy termini of proteins. 
Carboxypeptidase Y is a preferred enzyme for use in 
this invention. CPD-Y is an enzyme from yeast fungi 
possessing a serine residue in its catalytic site, and is 
characterized by its ability to catalyze various reactions 
depending on the pH of the reaction mixture. Further 
more, CPD-Y is a preferred enzyme for use in the label 
ing process of the present invention because it rapidly 
transpeptidates. 
It is to be understood that the enzyme may be immo 
bilized or chemically modified to retain or improve 
stability and appropriate enzymatic activity. It is also to 
be understood that the enzyme source may be yeast, 
animal, vegetable, or microbial. Enzymes produced by 
the technique of molecular cloning, either of naturally 
occurring enzymes or synthetically produced by muta 
tion or recombination, are also included in the inven 
t1O. 
Immobilizing Supports 
Immobilizing supports useful in the present invention 
are inorganic or organic materials functionalized so that 
a reaction can occur between the nucleophile or linker 
arm and the support. When the former reaction is em 
ployed, the support will be functionalized with a specifi 
cally reactive group mentioned above. When the latter 
reaction is employed, the support will be functionalized 
with the combining group for the other functional 
group mentioned above. In this case also, the reactive 
substituent may be chelating ferromagnetic groups. The 
immobilizing support then has the appropriate charac 
ter to produce binding. With a ferromagnetic group, the 
support may be magnetic wire that is rendered inert to 
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the reaction medium e.g., with teflon. Passing a current 
through the wire will establish the magnetism needed to 
cause binding. Alternatively, a magnet external to the 
system (i.e. outside the chromatographic medium) can 
be used to cause binding to the support. With the chelat 
ing group, the support may be an immobilized metal or 
other chelate. 
The support may be a porous or semiporous solid. 
Preferably, it is biologically inert and insoluble. Materi 
als that may be used as supports include fibers, sheets, 
microspheres, particles, beads, membranes, and the like. 
The surface of the immobilizing support of the pres 
ent invention is preferably porous. The use of sub 
stances having a porous surface, such as substantially 
spherical polymeric beads or microspheres of agarose 
allows large surface areas for the attachment of protein 
at high density. A surface is considered porous where 
the size of the majority of the pores in the material is 
sufficiently large so as to allow the migration of the 
protein into the interior of the spheres. The size and 
shape of the support may be varied widely, depending 
on the particular protein and its intended use. 
The immobilizing supports include a wide variety of 
substances. The choice of support, however, depends 
upon the choice of the nucleophilic and/or linker arm as 
well as on the intended use of the immobilized protein. 
The coupling reactions, nucleophile, specifically reac 
tive group and reactive group all are compatible as 
described above. In particular, the support is chosen 
such that the nucleophile will readily couple to the 
support or support-linker arm combination in prefer 
ence to any other reactive sites on the protein. For 
example, cysteine may be used as the amino acid nucleo 
phile to couple with a protein with no sulfhydryl groups 
eg. an antibody. A support or support-linker arm specif. 
ically reactive group is chosen that would react with 
the sulfhydryl moiety, for example, an organometallic 
group such as an organo mercury compound. Alterna 
tively, 2-amino-hex-4-enoic acid may be the amino acid 
nucleophile, and a specifically reactive group for the 
support may be one that would specifically react with 
the unsaturated side chain, as for example through a 
Diels Alder reaction. Another alternative is the choice 
of a photoaffinity label such as N-hydroxy succinimi 
dyl-4-azidosalicylic acid side chain, and an arylamine as 
the specifically reactive group on the attached sub 
stance. This salicylic side chain is to be coupled to the 
epsilon amino group of a lysine before the photo addi 
tion so that it will not be reactive with the amino groups 
of the protein. Photoreaction under, for example, u.v. 
light, will accomplish the desired photo binding reac 
tion. Moreover, if a linker arm is used, available groups 
on the support act as the reactive group. The other 
functional group of the linker arm is appropriately 
chosen to bind with the reactive group. 
Bioactive Agents 
Included within the invention is a method for attach 
ment of a bioactive agent to a protein at a site remote 
from the active site. These bioactive agents can be car 
ried or transported by the protein to a site where they 
can perform a desired reaction. 
The bioactive (biologically active) agent includes 
physiologically or pharmacologically active substances 
that act locally or systemically in the body. Examples of 
biologically active agents include peptide drugs, protein 
drugs, desensitizing agents, antigens, vaccines, anti 
infectives, antibiotics, antimicrobials, antiallergenics, 
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steroidal anti-inflammatory agents, decongestants, miot 
ics, anticholinergics, sympathomimetics, sedatives, hyp 
notics, psychic energizers, tranquilizers, androgenic 
steroids, estrogens, progestational agents, humoral 
agents, prostaglandins, analgesics, antispasmodics, anti 
malarials, antihistamines, cardioactive agents, nonste 
roidal anti-inflammatory agents, antiparkinsonian 
agents, antihypertensive agents, g-adrenergic blocking 
agents, nutritional agents, metal compounds, anti-can 
cer compounds such as fluorinated nucleotides, nucleo 
tide analogs, cytosine arabinocide, 5-fluorouracil, ricin 
A, tetanus toxin, cyclic therapeutic peptides such as 
anamycin, erythromycin, cyclosporin, AZT, and alka 
loids. Also, various forms of the biologically active 
agents may be used. Forms such as uncharged mole 
cules, molecular complexes, salts, ethers, esters, and 
amides are included. 
The bioactive agents are functionalized to carry spe 
cifically reactive groups for coupling to the nucleophile 
directly. Alternatively, appropriate available combining 
groups on the bioactive agent can be reacted with the 
other functional group on a linker arm. Preferably, this 
functionalization will be accomplished with a group 
already present within the agent. 
Conditions for Primary Coupling Reaction 
The conditions for the primary coupling reaction 
efficiently favor condensation, transpeptidation or 
transesterification over peptide cleavage. As can be 
seen from the following discussion of the application of 
the primary coupling reaction to antibody protein, these 
conditions generally involve control of pH, tempera 
ture, reactant concentrations, enzyme concentration 
and incubation time. 
The conditions for condensation and transpeptidation 
are basic which also disfavors peptide cleavage by hy 
drolysis. Preferably they are within range of about pH 
8.5 to 11. The selection of condensation over transpepti 
dation is made kinetically in that transpeptidation is 
completed quickly while condensation occurs slowly. 
In particular, transpeptidation occurs between 5 sec 
onds and 1.4 hours while condensation occurs between 
2 and 24 hours. 
Transesterification occurs under moderately acidic 
conditions which disfavor hydrolysis. Preferably the 
pH is less than about 6 and greater than about 3. A high 
molar concentration of the alcohol nucleophile is also 
important for transesterification. 
The reaction temperature is the functional range of 
the enzyme, preferably up to about 40 C. 
The concentrations of the reactants and enzyme are 
adjusted to provide optimum results. Generally, the 
highest possible concentrations of enzyme nucleophile 
and protein are used that coincide with an appreciable 
primary coupling reaction rate. Preferably, the protein 
is present at a concentration of from about 1 M to 
about M, especially up to about 1 mM when the pro 
tein is an antibody. The nucleophile or intermediate 
incorporating the nucleophile is preferably present at a 
concentration of at least 0.05 molar and especially a 
concentration of from about 0.1 to 2 molar. The enzyme 
is preferably present at a concentration of about 1 to 100 
LM, preferably about 1 to 100 uM. 
The incubation time (reaction time) of the protein and 
the nucleophile is from about 0.2 to 10 hours, preferably 
from 1.0 to 8 hours for condensation while for transpep 
tidation or transesterification, it is from about 30 sec 
onds to about 1.5 hours. 
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Specific Embodiments, Antibody Protein 
The pH of the reaction between an antibody and 
nucleophile determines the dominant enzymatic activity 
exhibited by the carboxypeptidase enzymes. Different 
reaction courses are possible at different pH values. The 
incorporation of a nucleophile by condensation, tran 
speptidation or transesterification depends upon which 
reaction course dominates in the incubation mixture. 
At neutral pH values, hydrolysis of peptide bonds is 
generally considered to be the dominant activity. As the 
pH increases, the hydrolysis activity decreases and the 
condensation and transpeptidation reactions become the 
prominent activities of the enzyme. When the pH is 
maintained at from about 8.5 to 11.0, preferably 9.5, the 
transpeptidation and condensation reaction are favored 
with the former being kinetically favored (i.e. happens 
fast). Typically, the transpeptidation reaction is pre 
ferred over condensation because it occurs rapidly in 
about 30 seconds to about 1 hour. When the pH is low 
such as 3.0 to 6.0 and the molar concentration of alcohol 
nucleophile is high, transesterification is favored. This 
reaction cleaves the C-terminal amino acid residue of 
the protein and substitutes the alcohol nucleophile by 
enzyme displacement. 
In several studies, the pH dependence of amino acid 
nucleophile addition by condensation with an antibody 
was examined and the details are described in the fol 
lowing examples section. The results of these studies, as 
depicted in FIG. 1, show that nucleophile incorporation 
is higher at higher temperatures and at higher values of 
pH. At a pH of 7.5, the nucleophile incorporation was 
observed to increase initially, followed by a decrease in 
incorporation and then an additional increase. The first 
incorporation is due to transpeptidation. The decrease 
in incorporation is due to partial loss of the incorpo 
rated nucleophile by the disfavored hydrolysis reaction. 
The second incorporation is due to the slower addition 
of the nucleophile by condensation. 
The effect caused by variation of the concentration of 
the reactants in the incubation mixture was also studied 
and the results are shown in Table 2. As generally indi 
cated above, concentration directly affects rate and 
amount of incorporation. The details of the study are 
provided in the following examples section. 
TABLE 2 
Effect on Condensation Reaction 
of Variation of Incubation Conditions 
SER/ 
Time? Abb Serb CPD-Yc Abd 
(hrs) (mg/ml) (mM) (M) Ratio Comments 
8 4. 230 20 3.3 Antibody Conc. 
- 12.7 234 20 4. Varied 
18.8 232 20 1.2 
9 2.3 O 20 0.16 Serine Conc. 
2.3 10 20 0.14 Varied 
12.3 220 20 34 
12.3 330 20 68 
5 0.5 22 5 0.14 CPD-Y Conc. 
0.8 12 1. 0.5 Waried 
18 20 16 1.6 
8 7.7 20 2.4 No Cosolvent 
7.7 75 20 4.2 30% glycerol 
27 0.5 78 20 0.4 Fi-monoclonal 
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TABLE 2-continued TABLE 3 
Effect on Condensation Reaction Condensation to Attach Nucleophile 
of Variation of Incubation Conditions Time Ab Label CPD-Ye Label/Abd Labele 
SERM 5 (hrs) (mg/ml) (mM) (M) Ratio Type 
Timea Abb Serb CPD-Yc Abd 8.5 8.7 188 20 0.5 Taurine 
(hrs) (mg/ml) (mM) (M) Ratio Comments 8.5 14.6 44 20 1.2 Alanine 
11. 78 20 16.9 Fl-polyclonal 8.5 18.8 232 20 1.2 Serine 
Sir R. R. (as - miscay. Elias. (A - nibody. Calculated from concentration of stock solution. O its from concentration of stock solution. 
Molar ratio, determined as described in methods section. The data shows results of Amino acid used for labeling reaction. 
a single representative experiment. Each experiment was repeated several times with 
similar results. 
Measurement made or change from standard method (see text for details). Although SOne quantitative variation in the amount 
of label incorporation was observed in duplicate experi 
The distribution of the nucleophile (labeled amino) ments conditions, this was within experimental error. 
acid between the carboxy termini of heavy and light The variation was probably due to the difficulty of the 
chains of the antibody was also investigated, and the separation required for the accurate assessment of the 
details are given in Example 4. The results indicate that label incorporation. High concentrations of unbound 
the labeled amino acid is preferentially incorporated label were essentially completely and rapidly separated into the heavy chain. At least about 70 percent of the from the relatively small quantities of antibody. Rapid incorporated nucleophile is located on the heavy chain. removal of the high concentations of amino acid gener 
Generally, the L-isomers of amino acids are incorpo- ally hinder a shift in the equilibrium, which would allow 
rated by this method, with incorporation occurring E. "it E" to hydrolyze the attached label 
substantially completely at the carboxyl termini of the 25 On the at ome small amount of label, how 
heavy chains of antibodies. i apparent y As times, causing quantitative 
Although the light chain of the antibody is labeled by E". n alGREE 
this reaction to a certain extent, it is not located near the lacking carboxypeptidase Y for each determination. 
antigen-binding region. Therefore, little effect, if any, an added precation, the trailing portion of the antibody 
on the function of the antibody is noted as a result of this 30 peak was not included in the quantitation. 
interact1O. As shown in Table 3, the enzyme incorporates ala 
The antigen-binding capacity of the labeled antibod- nine to about the same degree as serine. The enzyme 
ies as compared to that of the unlabeled antibodies was was also found to incorporate taurine, an amino acid not 
also studied. (See Examples 5 and 6.) For the anti- 35 usually found in proteins. The incorporation of taurine 
asparagine synthetase antibodies the average binding was found to be somewhat limited by the solubility of 
capacity was determined to be 100.1 percent of the the free amino acid, however. 
binding capacity with 0.6 serines incorporated per anti- This method of binding an antibody to a nucleophile 
body. The anti-F1 antibodies labeled as in Table 2 were provides a means of immobilizing, labeling or augment 
also assayed to determine their binding capacity. The ing antibodies without loss of antigen-binding capacity. binding capacity was found to be 105 percent for the This is due to the primary coupling reaction of the 
monoclonal antibody and 114 percent for the polyclonal nucleophile with the antibody by condensation, tran 
antibody compared to the unlabeled controls. These speptidation or transesterification. 
values are an average of four determinations. The slight Various nucleophiles can be bound to other func increases found for the labeled antibodies over the con. 4s inal Proteins, using similar experimental parameters. 
trols are due to experimental errors and are not signifi- The amino acid or amine nucleophile, enzyme, protein, 
cant. These results show no significant loss of antigen and bioactive agent, label or immobilizing support, 
binding as a result of label attachment. however, are generally chosen so as to enhance specific 
Similar reaction conditions of temperature, pH, and St. EE t.. t 
concentrations C2 be established for protein incorpora- 50 bound to remote from its E. an e 
tion of any of the amino acid or amine nucleophiles or The invention will be further characterized by the 
intermediates as mentioned above. following examples. These examples are not meant to 
Demonstration of Attachment limit the scope of the invention that has been set forth in 
ss the foregoing description. Variation within the con The results of some experiments wherein other amino cepts of the invention are apparent to those skilled in the 
acids were used as radioactive labels are shown in Table art. 
3. The condensation reactions were carried out gener- Examples 1-8 are standard methods for condensation, 
ally as described in Example 9 and assayed for label transpeptidation and transesterification. Example 9 
incorporation as described in Example 3. The concen- 60 demonstrates condensation. Examples 10 and 11 dem 
trations of antibody and amino acid shown in Table 3 onstrate transpeptidation. Examples 12 and 13 demon 
represent actual measured concentrations. The concen- strate transesterification. 
tration of carboxypeptidase Y is calculated from the EXAMPLE 1. 
concentration of the stock solution used. The values of 
label incorporation are given as label incorporated per 65 Antibody Preparation 
antibody molecule above the value of the control, 
which was incubated under the same conditions with 
out the addition of enzyme. 
Anti-asparagine synthetase monoclonal antibodies 
and anti-Fl ATPase monoclonal and polyclonal anti 
bodies were obtained from laboratory stocks. Mono 
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cional antibody stocks were obtained in the form of 
mouse Ascites tumor fluids and polyclonal antibody 
stocks were obtained from rabbit serum. Antibodies 
from either source were purified by addition of solid 
ammonium sulfate to a concentration of 50% of the 5 
saturation level. The precipitated protein was collected 
by centrifugation and dissolved in a minimal amount of 
i0 mM Tris-HCl Tris, tris(hydroxymethyl)aminome 
thane (pH 7.5). The preparation was then subjected to 
a second ammonium sulfate treatment until a 50% satu- 10 
ration level was reached. The precipitate was then col 
lected by centrifugation. The purified antibodies were 
dissolved in a minimal annount of water and dialyzed for 
18 to 24 hours against 10 mM sodium bicarbonate at 4 
C. This dialysis step was necessary to remove the resid-1s 
ual ammonium sulfate that was found to inhibit the 
activity of carboxypeptidase Y. The purified antibodies 
were stored in aliquots at -20° C. until needed. 
Unless otherwise noted, these three antibodies were 
used in each of the following examples. The term "anti body" as used herein means anti-asparaginine synthe 
tase monoclonal antibody, and anti-F1 ATPase mono 
and polyclonal antibodies. 
EXAMPLE 2 
5 Label Preparation 2 
Serine was used initially as 3H-serine and in latter 
experiments C-serine was used. All other amino acids 
used were 3H-amino acids. Radioactive amino acids 
were purchased from Amersham (Arlington Heights, 30 
Ill.). Unlabeled serine was from Fluka (Ronkonoma, 
N.Y.). Radioactive amino acids were diluted with unla 
beled amino acid to a specific activity of 0.5 to 2 mCi 
per millimole. The diluted amino acid was then purified 
by repeated precipitation with ethanol at -20° C. 35 
These precipitation steps were required to reduce non 
specific binding of the amino acid to the antibodies. The 
amino acid was stored as an aqueous solution at 4 C. 
The specific activity of the diluted, purified amino 
acid was determined as follows, and used in subsequent 40 
calculations of label incorporation. The quenched, de 
tectible radioactivity was determined under conditions 
identical to those used in the measurement of label in 
corporation. A known volume of the amino acid solu 
tion was diluted to 1.0 ml with 0.1M sodium phosphate 45 
(pH 6.8). This diluted sample was counted in a Beckman 
LS-100 liquid scintillation counter (Beckman Instru 
ments, Fullerton, Calif.) with 10.0 ml 3a70b scintillation 
fluid (Research Products, Elkgrove, Ill.). The amino 
acid concentration of the stock amino acid solution was 50 
determined on a known volume by assay of the amino 
groups with the ninhydrin assay; see S. Moore et al., J. 
Biol. Chen., 176, 367-388 (1948). A standard solution 
was prepared for this assay by dissolving glycine in 
water at 0°C. to obtain a saturated solution. The liquid 55 
was separated from any undissolved solid glycine, 
warmed to room temperature, and used as a standard. 
The concentration of the standard was assumed to be 
1.89M; see J. B. Dalton et al., J. Biol. Chenn., 103, 549 
(1933). From these measurements, the quenched value so 
of CPM/nmole was calculated and used in subsequent 
calculations. 
EXAMPLE 3 
Label Incorporation Assays 65 
The unbound amino acids were separated from the 
antibody by gel filtration HPLC. A 20 ul sample of the 
reaction mixture after incubation was applied to a GPC 
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300 gel filtration column (Synchrom, Linden, Ind.) and 
eluted with 0.1M sodium phosphate (pH 6.8). The 
HPLC system employed for this purpose consisted of a 
dual pump gradient system and a variable wavelength 
UV monitor produced by ChemResearch (ISCO, Lin 
coln, Neb.). The absorbance peak, monitored at 280 nm, 
corresponding to the antibody was collected. In order 
to ensure that complete removal of the unbound amino 
acid from the antibody, only the first of the absor 
bance peak was collected. The collected antibody solu 
tion was diluted to 1 ml with the elution buffer. 
The antibody concentration in the collected solution 
was determined by measurement of the absorbance at 
280 nm, assuming a standard absorbance of 1.46 absor 
bance units/mg. The incorporated amino acid was de 
termined by counting 1.0 ml of the collected antibody 
solution using 10 ml 3a70b liquid scintillation fluid. The 
amount of label incorporated was calculated using the 
corrected specific activity for the amino acid described 
above. The molar concentration of the antibody was 
calculated assuming a molecular weight of 150,000; see 
B. R. Champion et al., Immunology, 54,513-519 (1985). 
The reported label incorporation is the difference be 
tween the values obtained for the samples with and 
without carboxypeptidase Y. The results of the label 
incorporation are discussed in the foregoing specific 
embodiments section in conjunction with FIG. 2. 
EXAMPLE 4 
Antibody Chain Separation 
This example shows the specificity of nucleophile 
coupling to the heavy chain of an antibody as discussed 
in the foregoing specific embodiments section. 
Separation of the heavy and light chains of the anti 
body was performed on both labeled and control (unla 
beled) antibodies. The samples were labeled as de 
scribed above. Following the incubation, the antibodies 
were precipitated by addition of ammonium sulfate to a 
concentration of 50% of saturation. The precipitate was 
collected by centrifugation and the pellet was dissolved 
in a denaturing buffer (pH 6.8) consisting of 100 mM 
sodium sulfate, 2M urea, 2% sodium lauryl sulfate (SDS), 1% B-mercaptoethanol, and 25 mM 4-morpho 
line ethanesulfonic acid (MES). The sample was incu 
bated at 100° C. for 5 minutes to ensure complete dena 
turation of the protein. The antibody chains were sepa 
rated by gel filtration HPLC using an Altex TSK-125 
column (Biorad, Richmond, Calif.) equilibrated with 
the denaturing buffer. The effluent was monitored at 
280 nm. The peaks corresponding to the heavy and light 
chains of the antibody were collected separately. The 
collected samples were diluted to 1.2 ml with the dena 
turing buffer. 
The amount of amino acid incorporated into each 
chain was determined by counting 1.0 ml of each sam 
ple with 10 ml 3a70b liquid scintillation fluid. Due to 
interference of the denaturing buffer components the 
amount of protein in each sample could not be deter 
mined by the methods used above or by other com 
monly employed methods. An assay developed for this 
purpose consisted of adding 25 ul of 30% acrylamide, 
0.8% bioacrylamide, to 50 ul of the sample to be as 
Sayed. The mixture was polymerized by addition of 1.5 
ul 10% ammonium persulfate and ul N,N,N',N' tet 
ramethylethylenediamine. The interfering buffer com 
ponents were separated from the solidified sample by 
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washing with 2 aliquots (2 ml) 10% trichloroacetic acid, 
3 aliquots (2 ml) 10% acetic acid and 3 aliquots (2 ml) 
5% methanol, 7.5% acetic acid. The protein was 
stained with Coomassie Blue R-250 Commission on 
Biological Stains Number 42660). Following extensive 
washing with 30% methanol, 7.5% acetic acid to re 
move unbound dye, the bound dye was eluted by incu 
bation with SDS, sodium bicarbonate, and methanol. 
The absorbance of the eluted dye was measured and the 
protein content of the sample was determined by com 
parison with standard protein solutions assayed in an 
identical manner. 
The measured protein content and amino acid incor 
poration for each chain were used to calculate the label incorporation per polypeptide chain. In these calcula 
tions, the molecular weights of the heavy and light 
chains were taken to be 50,000 and 25,000, respectively; 
see B. R. Champion, et al., supra. The results based 
upon the data obtained (not shown) are discussed in the 
foregoing specific embodiments section and indicate at 
least a 70% incorporation in the heavy chain. 
EXAMPLE 5 
Anti-Asparagine Synthetase Antibody 
Immunoprecipitation 
This example shows that the attachment of the nu 
cleophile does not affect the antigen binding capacity of 
the antibody as discussed in the foregoing specific em 
bodiments section. 
Antibodies, both labeled as described above and con 
trols, were assayed by immunoprecipitation to deter 
mine their capacity to bind antigen. An aliquot of the 
incubation mixture was assayed to determine the extent 
of label incorporation. The remainder of the incubation 
mixture (80 ul ) was added to 420 ul of a pancreas 
extract containing asparagine synthetase; see C. A. 
Luehret al., J. Biochem. Biophys. Methods, 3, 151 (1980). 
The pH of the mixture was adjusted to 7.5. Crude pro 
tein A extract (Sigma Chemical Co., St. Louis, Mo.) 
was washed twice by centrifuging the solution and 
suspending the pellet in 50 mM Tris-HCl (pH 7.5). This 
washed extract was suspended in 5 times its original 
volume of 50 mM Tris-HCl (pH 7.5). After incubation 
of the antibody with the pancreas extract for 18 hours at 
37 C., 1 ml of crude, washed protein A extract was 
added and incubation was continued for an additional 2 
hours. The mixture was then centrifuged to collect the 
Protein A/antibody/Asparagine Synthetase complex. 
The pellet was washed twice with 50 mM Tris-HCl (pH 
7.5) and then incubated for 2 hours with 200 ul of an 
assay solution (pH 7.5) containing 100 mM Tris-HCl, 10 
mM MgCl2, 10 mM ATP, and 10 mM glutamine. The 
solid material was removed by centrifugation and the 
resulting solution was stored at -20 C. for amino acid 
analysis. 
Amino acid analysis was accomplished by HPLC 
separation of the amino acids following derivitization 
with B-mercaptoethanol and o-phthaldialdehyde; see S. 
Unnithan et al., Anal. Biochem., 136, 195 (1984). The 
HPLC system used consisted of a dual pump gradient 
Beckman HPLC system with a Dupont model 836 fluo 
rescence detector (E.I.Dupont, Des Plains, Ill.) and 
Integrator (Spectra-Physics, Santa Clara, Calif.). The 
column used was a Rainin Microsorb Cl reversed phase 
column (Rainin Instruments, Woburn, Mass.). The 
binding capacity of the antibodies was assessed by mea 
surement of the hydrolysis of glutamine to glutamate by 
the asparagine synthetase bound to the Protein A/anti 
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body complex. The activity of the bound enzyme was 
determined by the ratio of the integrated areas of the 
glutamate and glutamine peaks. The percent activity for 
the labeled antibodies relative to the unlabeled controls 
was calculated from these Glu/Gln ratios. The results 
generally indicate that the capacity of antibody with 
coupled nucleophile is the same as free antibody. See 
the discussion at pages 30 and 31. 
EXAMPLE 6 
Anti-F1 ATPase Antibody Immunoprecipitation 
This example shows the same effect illustrated in 
Example 6. 
Both monoclonal and polyclonal antibodies, labeled 
as described above and unlabeled controls, were as 
sayed by immunoprecipitation to determine their capac 
ity to bind antigen. An aliquot of the incubation mixture 
was assayed to determine the extent of label incorpora 
tion. The remainder of the incubation mixture (80 ul) 
was added to 420 pull of a 0.2 mg/ml solution of purified 
bovine F1-ATPase; see A. F. Knowles et al., J. Biol. 
Chem, 247, 6617 (1972). The pH of the reaction mixture 
was adjusted to 7.5. Crude protein A extract was 
washed twice by centrifuging the solution and suspend 
ing the pellet in 50 mM Tris-HCl (pH 7.5). This washed 
extract was suspended in 5 times its original volume of 
50 mM Tris-HCl (pH 7.5). After incubation of the anti 
body with the pancreas extract for 18 hours at 37 C., 1 
ml of crude, washed protein A extract was added and 
incubation was continued for an additional 2 hours. The 
mixture was then centrifuged to collect the Protein 
A/antibody/F1-ATPase complex. The pellet was 
washed twice with 50 mM Tris-HCl (pH 7.5) and then 
incubated for 2 hours with 100 ul of an assay solution (pH 8.0) consisting of 50 mM N-tris(hydroxymethyl)- 
methylglycine (Tricine), 5 mM MgCl2, and 5 mM 
ATP. The solid material was removed by centrifugation 
and the resulting solution was stored at -20° C. for 
analysis. An additional control lacking antibodies was 
treated similarly. 
ATPase activity was determined by measurement of 
the released phosphate; see S. Unnithan et al., vide 
supra. The bound enzyme was assessed by the produc 
tion of inorganic phosphate above the value given by 
the control which lacked antibody. The percentage of 
binding capacity of the labeled versus unlabeled anti 
bodies was calculated as the ratio of the labeled to the 
unlabeled activities. The results are discussed in the 
specific embodiments section at pages 30 and 31. 
EXAMPLE 7 
Stability of Labeled Antibodies 
The stability of the incorporated label under different 
storage conditions was also determined. For this experi 
ment, label incorporation was assayed on an aliquot of . 
the incubation mixture. The antibodies in the remainder 
of the sample were precipitated with ammonium sulfate 
and dissolved in water. An aliquot was stored at 4 C. 
and another at -20°C. for 8 days. Following the stor 
age period the incorporated label in these samples was 
determined and compared to the first sample. The re 
sults are shown in Table 4. 
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TABLE 4 
Label Stability 
Conditions Ser/Abh % of t = 0 
t = 0 0.55 00 5 
8 days, 4 C. 0.63 6 
8 days. -20° C. 0.49 88 
Storage conditions following labeling incubation at 37 C. and ph9.5, 
Molar ratio, determined as described in methods section, average of two determina 
tions. 
Average percent gain or loss of activity compared to no incubation following 
labelling incubation. O 
EXAMPLE 8 
Specificity of Incorporation 15 
In order to verify that the incorporation is due to 
catalysis by the enzyme, L-serine at different concentra 
tions and D,L-serine were incorporated by the standard 
method. These results are shown in Table 5. The incor 
poration of D,L-serine is comparable to incorporation 
of L-serine at half the concentration of the D.L-serine. 
If can be explained by the incorporation of only the 
L-isomer. This stereospecificity has been shown for 
carboxypeptidase Y under other conditions; See R. 
Hayashi et al., J. Biochem, 77, 69 (1975). Nonspecific 
absorpotion or other nonenzymatic means of attach 
ment which might occur under these conditions would 
be expected to incorporate both isomers. 
TABLE 5 
20 
25 
30 Stereospecificity 
Timed Ab Serb CPD-Yc Ser/Abd 
(hrs) (mg/ml) (mM) (M) Ratio Comments 
8 7.9 198 20 1.7 L-serine 
10. 126 20 0.9 L-serine 35 
8, 177 20 0.5 D.L-serine 
Time of labeling incubation at 37' C. pH 9.5. 
Measured concentration in incubation mixture. 
Calculated from concentration of stock solution. 
Molar ratio. determined as described in methods section. 
Label used. 
40 
EXAMPLE 9 
Standard Conditions for Antibody Labeling 
(Condensation) 45 
The following conditions and methods for label in 
corporation by condensation were used for all runs 
unless otherwise indicated. A mixture of the antibody 
and amino acid stock solutions was made and diluted 
with water to the desired concentrations. The pH of this 
solution was measured with pH indicator paper (Fisher 
Chemical, Springfield, N.J.) and adjusted to 9.5 with 
0.5M sodium hydroxide. From this solution a 4 Jul por 
tion was removed and diluted to 1.0 ml with 0.1M so 
dium phosphate (pH 6.8). The absorbance of this solu 
tion was measured at 280 nm using a Beckman DU-50 
spectrophotometer. The concentration of the antibody 
in the solution was calculated assuming a standard ab 
sorbance of 1.46 absorbance units per mg of antibody; 
see A. Good et al., in Selected Methods in Cellular Im 
munology, Mishell & Shiigi eds., W. H. Freeman & Co., 
San Francisco, p. 284 (1980). The concentration of the 
amino acid in the incubation mixture was determined by 
counting a small sample of the diluted mixture follow 
ing further dilution to 1.0 ml with 0.1M sodium phos 
phate (pH 6.8). The amino acid concentration was cal 
culated from the counts present using the corrected 
specific activity determined previously and correcting 
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for both dilutions, as well as the 5% dilution described 
below. 
The remainder of the undiluted mixture was divided 
into two equal parts. To one of these portions was 
added the carboxypeptidase Y (affinity purified, E.C. 
3.4.16.4, free from endoproteinase contamination) stock 
solution (24.3 mg/ml) at 5ul per 100 ul of mixture. The 
other portion served as a control and was diluted simi 
larly with water. Once these two solutions were pre 
pared, they were incubated in a 37° C. water bath for 
approximately 8 hours. The samples were then removed 
from the water bath and either analyzed immediately or 
frozen and used as soon as possible. The results of the 
variation in concentration of the label are provided in 
foregoing Table 2 and discussed in conjunction there 
with. 
EXAMPLE 10 
Transpeptidation with a Tetrapeptide Model 
This example illustrates the synthesis of the tetrapep 
tide Benzoyl-Thr-Val-Ser-(14C)Ser from Benxoyl-Thr 
Val-Ser-Ser. About 5 to 10 mM of Benzoyl-Thr-Val 
Ser-Ser (BTVSS) may be dissolved in 2 ml of 50 mM 
sodium carbonate buffer (pH 9.5) containing 1 mM 
EDTA and 0.25M 14-C-serine. The reaction may be 
initiated by the addition of 5 uM carboxypeptidase Y 
enzyme. At preset time intervals, the reaction may be 
sampled by removing 0.2 ml aliquots and diluting with 
0.2 ml of acetonitrile, then adding 0.1 ml of 0.12M acetic 
acid. 
The samples may then be subjected to high pressure 
liquid chromatography (HPLC) using a reverse phase 
C-18 column developed with a linear gradient con 
structed from two solvents. A first solvent (A) can be 
95% of 10 mM sodium acetate, 5% acetonitrile pH 4.5 
and the second (B) can be 60% acetonitrile. A gradient 
can be developed over a 30 min time period and can be 
initiated by mixing solvents A and B at the proportions 
of 1 part A and 0 parts B and ended with 40 parts A and 
60 parts B. The flow rate can be maintained at 1.0 ml per 
min. The peptide should elute and be free of serine and 
BTVS (hydrolyzed BTVSS). 
Separate amino acid analyses of the HPLC fraction 
should show the peptide to contain one residue each of 
Thr, Val and two residues of Ser. The specific activity 
of both the serine recovered from amino acid analysis 
and that of the peptide should be the same on a molar 
basis. 
EXAMPLE 11 
Transpeptidation with Anti-Asparagine Synthetase 
Monoclonal Antibody 
This example illustrates the synthesis of C-Nor-C- (C)Ser anti-asparagine synthetase monoclonal anti 
body (Nor-Mab-Ser") from anti-asparagine synthetase 
monoclonal antibody (Mab). About 0.2 mM of Mab 
may be dissolved in 2 ml of 50 mM sodium carbonate 
buffer (pH 9.5) containing 1 mM EDTA and 0.25M 
14-C-serine. The reaction may be initiated by the addi 
tion of 5 uM of carboxypeptidase Y enzyme. At preset 
time intervals, the reaction may be sampled by remov 
ing 0.2 ml aliquots and diluting with 0.2 ml of acetoni 
trile, then adding 0.1 ml of 0.12M acetic acid. 
The samples may then be subjected to high pressure 
liquid chromatography (HPLC) using a reverse phase 
C-18 column developed with a linear gradient con 
structed from two solvents. A first solvent (A) can be 
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95% of 10 mM sodium acetate, 5% acetonitrile pH 4.5 
and the second (B) can be 60% acetonitrile. A gradient 
can be developed over a 30 min time period and can be 
initiated by mixing solvents A and B at the proportions 
of 1 part A and 0 parts B and ended with 40 parts A and 
60 parts B. The flow rate can be maintained at 1.0 ml per 
min. The Nor-Mab-Ser" should elute and be free of 
serine and Mab. Separate amino acid analysis should 
show the Nor-Mab-Ser" to contain one residue of Ser. 
The specific activity of both the serine recovered from 
amino acid analysis and that of the Nor-Mab-Ser" 
should be the same on a molar basis. 
EXAMPLE 12 
Transesterification Using a Tetrapeptide Model 
This example illustrates the synthesis of Benzoyl-Thr 
Val-Ser-(14 C)OMe from Benzoyl-Thr-Val-Ser-Ser. 
About 5 to 10 mM of Benzoyl-Thr-Val-Ser-Ser 
(BTVSS) may be dissolved in 2 ml of 50 mM sodium 
phosphate/phosphoric acid buffer (pH 3.5) containing 1 
mM EDTA and 0.25 M 14C-methanol (MeOH). The 
reaction may be initiated by the addition of 5 uM of 
carboxypeptidase Y enzyme. At preset time intervals, 
the reaction may be sampled by removing 0.2 ml ali 
quots and diluting with 0.2 ml of acetonitrile, then add 
ing 0.1 ml of 0.12M acetic acid. 
The samples may then be subjected to high pressure 
liquid chromatography (HPLC) using a reverse phase 
C-18 column developed with a linear gradient con 
structed from two solvents. A first solvent (A) can be 
95% of 10 mM sodium acetate, 5% acetonitrile pH 4.5 
and the second (B) can be 60% acetonitrile. A gradient 
can be developed over a 30 min time period and can be 
initiated by mixing solvents A and B at the proportions 
of 1 part A and 0 parts B and ended with 40 parts A and 
60 parts B. The flow rate can be maintained at 1.0 ml per 
1. 
The peptide should elute and be free of methanol and 
BTVS (hydrolyzed BTVSS). Separate amino acid anal 
ysis should show the peptide to contain one residue 
each of Thr, Val and a Ser methyl ester. The specific 
activity of both the serine methyl ester recovered from 
amino acid analysis and that of the peptide should be the 
same on a molar basis. 
EXAMPLE 13 
Transesterification Using Anti-Asparagine Synthetase 
Monoclonal Antibody 
This example illustrates the synthesis of C methyl 
C-nor-Anti-asparagine synthetase monoclonal antibody 
ester (methyl Nor Mab) from anti-asparagine synthe 
tase monoclonal antibody (Mab). About 0.2 mM of Mab 
may be dissolved in 2 ml of 50 mM sodium phosphate/- 
phosphoric acid buffer (pH 3.5) containing 1 mM 
EDTA and 0.25M 14-C-Methanol. The reaction may be 
initiated by the addition of 5 uM of carboxypeptidase Y 
enzyme. At preset time intervals, the reaction may be 
sampled by removing 0.2 ml aliquots and diluting with 
0.2 ml of acetonitrile, then adding 0.1 ml of 0.12Macetic 
acid. 
The samples may then be subjected to high pressure 
liquid chromatography (HPLC) using a reverse phase 
C-18 column developed column developed with a linear 
gradient constructed from two solvents. A first solvent 
(A) can be 95% of 10 mM sodium acetate, 5% acetoni 
trile pH 4.5 and the second (B) can be 60% acetonitrile. 
A gradient can be developed over a 30 mintime period 
and can be initiated by mixing solvents A and B at the 
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proportions of 1 part A and 0 parts B and ended with 40 
parts A and 60 parts B. The flow rate can be maintained 
at 1.0 ml per min. The "methyl- Nor-Mab should elute 
and be free of methyl and Nor-Mab (hydrolyzed Mab). 
Separate amino acid analysis should show the "methyl 
Nor-Mab to contain one residue of methyl serine ester. 
The specific activity of both the methyl serine ester 
recovered from amino acid analysis and that of the 
"methyl-Nor-Mab should be the same on a molar basis. 
We claim: 
1. A method for forming a protein bound to an auxil 
iary substance, comprising: 
coupling a nucleophile to a protein having a C-ter 
minus amino acid with the C-terminus as a carbox 
ylic acid group, and an amino acid having a car 
bonyl group penultimate to the C-terminus amino 
acid by catalysis at acidic or basic pH with an exo 
peptidase enzyme to form an adduct, wherein the 
nucleophile is an amino acid, amine or alcohol 
having an amine or alcohol group and a side chain 
with a distinctive reactive substituent, and the cou 
pling is between the amine or alcohol group of the 
nucleophile and the C-terminus carboxylic acid 
group of the protein or the carbonyl group of the 
amino acid penultimate to the C-terminus of the 
protein; and 
binding the adduct to the auxiliary substance or its 
combination with a linker arm to form the bound 
protein, wherein the auxiliary substance or combi 
nation has a specifically reactive group that is cor 
relatively reactive toward the distinctive reactive 
substituent of the adduct, and the specifically reac 
tive group and the distinctive reactive substituent 
react with each other without substantially involv 
ing other groups of the protein to accomplish the 
binding; and 
wherein the bound protein is a straight chain of the 
protein, nucleophile and auxiliary substance bonded 
together or a straight chain of the protein, nucleophile, 
linker and auxiliary substance bonded together, and 
only two sites on each of the nucleophile and linker as 
well as only one site on each of the protein and auxiliary 
substance are chain binding sites. 
2. A method for forming a protein bound to an auxil 
iary substance, comprising: 
binding a nucleophile to the auxiliary substance or its 
combination with a linker arm to form an interme 
diate, wherein the nucleophile is an amino acid, 
amine or alcohol having an amine or alcohol group 
and a side chain with a reactive substituent, the 
auxiliary substance or combination has a reactive 
group that is reactive toward the reactive substitu 
ent of the nucleophile, and the binding is between 
the reactive substituent and the reactive group; 
and, 
coupling the intermediate to a protein having a C-ter 
minus amino acid having a carbonyl group with the 
C-terminus as a carboxylic acid group, and an 
amino acid penultimate to the C-terminus amino 
acid by catalysis at acidic or basic pH with an exo 
peptidase enzyme to form the bound protein, the 
coupling being between the amine or alcohol group 
of the nucleophile within the intermediate and the 
C-terminus carboxylic acid group of the protein or 
the carbonyl group of the amino acid penultimate 
to the C-terminus of the protein; and 
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wherein the bound protein is a straight chain of the 
protein, nucleophile and auxiliary substance bonded 
together or a straight chain of the protein, nucleophile, 
linker and auxiliary substance bonded together, and 
only two sites on each of the nucleophile and linker as 
well as only one site on each of the protein and auxiliary 
substance are chain binding sites. 
3. A method according to claim 1 or 2 wherein the 
auxiliary substance is an immobilization support, a label 
or a bioactive agent. 
4. A method according to claim 1 or 2 wherein the 
combination of auxiliary substance covalently bound to 
the linker arm having the specifically reactive func 
tional group terminating the free end of the linker arm 
is used. 
5. A method according to claim 1 or 2 wherein the 
catalysis conditions are basic and the nucleophile is an 
amino acid or amine. 
6. A method according to claim 5 wherein the cataly 
sis conditions include a rapid incubation time. 
7. A method according to claim 1 or 2 wherein the 
catalysis conditions are acidic and the nucleophile is an 
alcohol. 
8. A method according to claim 7 wherein the cataly 
sis conditions include a rapid incubation time. 
9. A method according to claim 1 or 2 wherein the 
protein is an antibody, an enzyme, an enzyme inhibitor, 
a protein hormone, a DNA binding protein, a regula 
tory protein or a DNA reading frame protein. 
10. A method according to claim 9 wherein the pro 
tein is an antibody having at least a heavy chain with a 
carboxyl terminus and the nucleophile is substantially 
completely bonded to the carboxyl terminus of the 
heavy chain of the antibody. 
11. A method according to claim 10 wherein the 
protein is a monoclonal antibody. 
12. A method according to claim 10 wherein the 
protein is a polyclonal antibody. 
13. The method according to claim 10 wherein the protein is an IgG immunoprotein. 
14. A method according to claim 1 or 2 wherein the 
nucleophile is an amino acid. 
15. A method according to claim 14 wherein the 
amino acid is selected from the group consisting of an 
aliphatic amino acid, an hydroxy amino acid, a sulfur 
containing amino acid, a diamino monocarboxylic acid, 
an aromatic amino acid, a heterocyclic amino acid and 
activated derivatives thereof. 
16. A method according to claim 15 wherein the 
amino acid nucleophile is serine, taurine, or alanine. 
17. A method according to claim 1 or 2 wherein the 
enzyme is an exocarboxypeptidase. 
18. A method according to claim 1 or 2 wherein the 
enzyme is a serine or cysteine exocarboxypeptidase. 
19. A method for preparing a labeled protein, com 
prising: 
coupling a nucleophile and a protein having a C-ter 
minus amino acid with the C-terminus as a carbox 
ylic acid group, and an amino acid having a car 
bonyl group penultimate to the C-terminus amino 
acid in a medium at an acidic or basic pH and in the 
presence of an exopeptidase enzyme to form an 
adduct, said nucleophile being an amino acid, 
amine or alcohol having an amine or alcohol group 
and a side chain with a distinctive reactive substitu 
ent selected from the group consisting of sulfhy 
dryl, hydroxyl, activated hydroxyl, olefinyl, acti 
wated ester, amino, azidyl, hydrazinyl, phosphora 
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midoyl, boronyl, ferrocenyl, ferro complexes and 
mixtures thereof, and the coupling is between the 
amino or alcohol group of the nucleophile and the 
C-terminus carboxylic acid group of the protein or 
the carbonyl group of the amino acid penultimate 
to the C-terminus of the protein; 
combining a label and a linker arm to form a combina 
tion, said label being fluorescent, nuclear magnetic, 
phosphorescent, colorimetric, magnetic, electron 
resonant or spectrometric and having at least one 
reactive group, said linker arm being a flexible or 
semi-flexible chain having a specifically reactive 
group that is correlatively reactive with the dis 
tinctive reactive substituent and another functional 
group that is reactive toward the reactive group of 
the label, and the combining is between the reac 
tive group of the label and the functional group of 
the linker arm; and, 
binding the adduct and the combination to form the 
labeled protein; wherein, 
the correlative reactivity of the specifically reactive 
group and the distinctive reactive substituent re 
sults in their reaction with each other without sub 
stantially involving other groups of the protein to 
accomplish the binding; and 
wherein the bound protein is a straight chain of the 
protein, nucleophile, linker and label bonded together, 
and only two sites on each of the nucleophile and linker 
as well as only one site on each of the protein and label 
are chain binding sites. 
20. A method for preparing a labeled protein, com prising: 
combining a label and a linker arm to form a combina 
tion, said label being fluorescent, nuclear magnetic, 
phosphorescent, colorimetric or spectrometric and 
having at least one combining group, said linker 
arm being a flexible or semi-flexible chain having a 
specifically reactive group that is or is rendered 
nonreactive with the combining group of the label 
and another functional group that is reactive 
toward the combining group of the label, and the 
combining being between the combining group of 
the label and the functional group of the linker arm; 
binding the combination and a nucleophile to form an 
intermediate, said nucleophile being an amino acid, 
amine or alcohol having an amine or alcohol group 
and a side chain with a reactive substituent that is 
reactive toward the specifically reactive group of 
the combination, and the binding is between the 
reactive substituent and the specifically reactive 
group; and, 
coupling the intermediate and a protein having a 
C-terminus amino acid with the C-terminus as a 
carboxylic acid being a carbonyl group, and an 
amino acid penultimate to the C-terminus amino 
acid in a medium at a acidic or basic pH and in the 
presence of an exopeptidase enzyme to form the 
labeled protein, the coupling being between the 
amine or alcohol group of the nucleophile within 
the intermediate and the C-terminus carboxylic 
acid group of the protein or the carbonyl group of 
the amino acid penultimate to the C-terminus of the 
protein; and 
wherein the bound protein is a straight chain of the 
protein, nucleophile, linker and label bonded together, 
and only two sites on each of the nucleophile and linker 
as well as only one site on each of the protein and label 
are chain binding sites. 
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21. A method for preparing an immobilized protein 
comprising: 
coupling a nucleophile and a protein having a C-ter 
minus amino acid with the C-terminus as a carbox 
ylic acid group, and an amino acid, having a car 
bonyl group penultimate to the C-terminus amino 
acid in a medium at an acidic or basic pH and in the 
presence of an exopeptidase enzyme to form an 
adduct, said nucleophile being an amino acid, 
amine or alcohol having an amine or alcohol group 
and a side chain with a distinctive reactive substitu 
ent selected from the group consisting of sulfhy 
dryl, hydroxyl, activated hydroxyl, amino, acti 
vated ester, olefinyl, azidyl, hydrazinyl, phos 
phoramidoyl, boronyl ferrocenyl, ferro complexes 
and mixtures thereof, and the coupling being be 
tween the amine or alcohol group of the nucleo 
phile and the C-terminus carboxylic acid group of 
the protein or the carbonyl group of the amino acid 
penultimate to the C-terminus of the protein; and, 
binding the adduct and an immobilization support to 
form the immobilized protein, wherein the support 
has at least one specifically reactive group that is 
correlatively reactive toward the distinctive reac 
tive substituent of the adduct, and the specifically 
reactive group and the distinctive reactive substitu 
ent react with each other without substantially 
involving other groups of the protein to accom 
plish the binding; and 
wherein the bound protein is a straight chain of the 
protein, nucleophile and immobilization support 
bonded together, and only two sites on the nucleophile 
as well as only one site on each of the protein and immo 
bilization support are chain binding sites. 
22. A method for preparing an immobilized protein, 
comprising: 
coupling a nucleophile and a protein having a C-ter 
minus amino acid with the C-terminus as a carbox 
ylic acid group, and an amino acid having a car 
bonyl group penultimate to the C-terminus amino 
acid in a medium at acidic or basic pH and in the 
presence of an exopeptidase enzyme to form an 
adduct, said nucleophile being an amino acid, 
amine or alcohol having an amine or alcohol group 
and a side chain with a distinctive reactive substitu 
ent selected from the group consisting of sulfhy 
dryl, hydroxyl, activated hydroxyl, amino, acti 
vated ester, olefinyl, azidyl, hydrazinyl, phos 
phoramidoyl, boronyl ferrocenyl, ferro complexes 
and mixtures thereof, and the coupling being be 
tween the amine or alcohol group of the nucleo 
phile and the C-terminus carboxylic acid group of 
the protein or the carbonyl group of the amino acid 
penultimate to the C-terminus of the protein; 
combining an immobilization support and a linker 
arm to form a covalently bound combination, said 
support having at least one combining group, and 
said linker arm being a flexible or semi-flexible 
chain having a specifically reactive group that is 
correlatively reactive with the distinctive reactive 
substituent of the adduct and another functional 
group that is reactive toward the combining group 
of the support, the combining being between the 
functional group and the combining group; and 
binding the adduct and the combination through 
reaction of the specifically reactive group and the 
distinctive reactive substituent to form the immobi 
lized protein; wherein, 
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the correlative reactivity of the specifically reactive 
group and the distinctive reactive substituent re 
sults in their reaction with each other without sub 
stantially involving other groups of the protein; 
and 
wherein the immobilized protein is a straight chain off 
the protein nucleophile, linker and immobilization sup 
port bonded together, and only two sites on each of the 
nucleophile and linker as well as only one site on each 
of the protein and immobilization support are chain 
binding sites, w 
23. A method for preparing an immobilized protein, 
comprising: 
combining an immobilization support and a linker 
arm to form a covalently bound combination, said 
support having at least one combining group, and 
said linker arm being a flexible or semi-flexible 
chain having a specifically reactive group that is or 
is rendered non-reactive with the combining group 
and another functional group that is reactive 
toward the combining group of the support, and 
the combining being between the combining group 
and the functional group; 
binding the combination and a nucleophile to form an 
intermediate, said nucleophile being an amino acid, 
amine or alcohol having an amine or alcohol group 
and a side chain with a reactive substituent that is 
reactive toward the specifically reactive group of 
the combination, and the binding being between 
the reactive substituent and the specifically reac 
tive group; and, 
coupling the intermediate and a protein having a 
C-terminus amino acid with the C-terminus as a 
carboxylic acid group, and an amino acid having a 
carbonyl group penultimate to the C-terminus 
amino acid in a medium at acidic or basic pH and in 
the presence of a exopeptidase enzyme to form the 
immobilized protein, the coupling being between 
the amine or alcohol group of the nucleophile 
within the intermediate and the C-terminus carbox 
ylic acid group of the protein or the carbonyl 
group of the amino acid penultimate to the C-ter 
minus of the protein; and 
wherein the immobilized protein is a straight chain of 
the protein, nucleophile, linker and immobilization sup 
port bonded together, and only two sites on each of the 
nucleophile and linker as well as only one site on each 
of the protein and immobilization support are chain binding sites. 
24. A method for preparing an immobilized protein, 
comprising: 
binding a nucleophile and an immobilization support 
to form an intermediate, said nucleophile being an 
amino acid, amine or alcohol having an amine or 
alcohol group and a side chain with a reactive 
substituent, said immobilization support having at 
least one specifically reactive group that is reactive 
toward the reactive substituent of the nucleophile, 
and the binding being between the reactive substit 
uent and the specifically reactive group; and, 
coupling the intermediate and a protein having a 
C-terminus amino acid with the C-terminus as a 
carboxylic acid group, and an amino acid having a 
carbonyl group penultimate to the C-terminus 
amino acid in a medium at acidic or basic pH and in 
the presence of an exopeptidase enzyme to form 
the immobilized protein, the coupling being be 
tween the amine or alcohol group of the nucleo 
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phile within the intermediate and the C-terminus 
carboxylic acid group of the protein or the car 
bonyl group of the amino acid penultimate to the 
C-terminus of the protein; and 
wherein the immobilized protein is a straight chain of 5 
the protein, nucleophile and immobilization support 
bonded together, and only two sites on the nucleophile 
as well as only one site on each of the protein and immo 
bilization support are chain binding sites. 
25. A method according to claim 21, 22, 23 or 24 
wherein the carboxyl terminus of the protein is coupled 
to the support. 
26. The method according to claim 21, 22, 23, or 24 
wherein the support is an inorganic support. 
27. A method according to claim 21, 22, 23, or 24 
wherein the support is an organic support. 
28. A method according to claim 21, 22, 23, or 24 
wherein the support is sheets or a particulate material. 
29. A method according to claim 28 wherein the 
particulate material is porous or semi-porous micropar 
ticles, microbeads, beads, spheres, gel particles or fibers. 
30. An immobilized protein prepared by a method 
according to claim 21, 22, 23, or 24. 
31. A method for preparing a protein-bioactive agent 
composition, comprising: 
coupling a nucleophile and a protein having a C-ter 
minus amino acid with the C-terminus as a carbox 
ylic acid group, and an amino acid having a car 
bonyl group penultimate to the C-terminus amino 
acid in a medium at an acidic or basic pH and in the 
presence of an exopeptidase enzyme to form an 
adduct, said nucleophile being an amino acid, 
amine or alcohol having an amine or alcohol group 
and a side chain with a distinctive reactive substitu 
ent selected from the group consisting of sulfhy 
dryl, hydroxyl, activated hydroxyl, amino, acti 
vated ester, olefinyl, azidyl, hydrazinyl, phos 
phoramidoyl, boronyl ferrocenyl, ferro complexes 
and mixtures thereof, and the coupling is between 
the amino or alcohol group of the nucleophile and 
the C-terminus carboxylic acid group of the pro 
tein or the carbonyl group of the amino acid penul 
timate to the C-terminus of the protein; and, 
binding the adduct and a bioactive agent to form the 
protein-bioactive agent composition, said bioactive 
agent having at least one specifically reactive 
group that is correlatively reactive toward the 
reactive substituent of the adduct wherein the spe 
cifically reactive group and the distinctive reactive 
substituent react with each other without substan 
tially involving other groups of the protein to ac 
complish the binding; and 
wherein the protein-bioactive agent composition is a 
straight chain of the protein, nucleophile and bioactive 
agent bonded together, and only two sites on the nu 
cleophile as well as only one site on each of the protein 
and bioactive agent are chain binding sites. 
32. A method for preparing a protein-bioactive agent 
composition, comprising: 
coupling a nucleophile and a protein having a C-ter 
minus amino acid with the C-terminus as a carbox 
ylic acid group, and an amino acid having a car 
bonyl group penultimate to the C-terminus amino 
acid in a medium at an acidic or basic pH and in the 
presence of an exopeptidase enzyme to form an 
adduct, said nucleophile being an amino acid, 
amine or alcohol having an amine or alcohol group 
and a side chain with a distinctive reactive substitu 
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ent selected from the group consisting of sulfhy 
dryl, hydroxyl, activated hydroxyl, amino, acti 
vated ester, olefinyl, azidyl, hydrazinyl, phos 
phoramidoyl, boronyl, ferrocenyl, ferro complexes 
and mixtures thereof, and the coupling is between 
the amine or alcohol group of the nucleophile and 
the C-terminus carboxylic acid group of the pro 
tein or the carbonyl group of the amino acid penul 
timate to the C-terminus of the protein; 
combining a bioactive agent and a linker arm to form 
covalently bound combination, said bioactive 
agent having at least one combining group, said 
linker arm being a flexible or semi-flexible chain 
having a specifically reactive group that is correla 
tively reactive toward the distinctive reactive sub 
stituent of the adduct and another reactive group 
that is reactive toward the combining group of the 
bioactive agent, and the combining being between 
the combining group and the reactive group; and 
binding the adduct and combination to form the pro 
tein-bioactive agent composition through the reac 
tion of the specifically reactive group and the dis 
tinctive reactive substituent; wherein, 
the correlative reactivity of the specifically reactive 
group and the distinctive reactive substituent re 
sults in their reaction with each other without sub 
stantially involving other groups of the protein; 
and 
wherein the protein-bioactive agent composition is a 
straight chain of the protein, nucleophile, linker and 
bioactive agent bonded together, and only two sites on 
each of the nucleophile and linker as well as only one 
site on each of the protein and bioactive agent are chain binding sites. 
33. A method according to claim 1, 20, 21, 22, 31 or 
32 wherein the distinctive reactive substituent and spe 
cifically reactive group are selected from the pairs con 
sisting of (a) a sulfhydryl group and a organometallic 
group, (b) an olefinyl group and a dienyl group, (c) a 
polar olefinic group and its corresponding monomer or 
substituted forms thereof, (d) an affinity complexing 
compound and its substrate, (e) a pair of hydroborated 
olefinic groups, (f) an aromatic amino group and an 
epoxy activated ester or aldehyde group, (g) an azidyl 
or hydrazinyl group and an aromatic amino group, (h) 
an aromatic alcohol and an activated ester group, and (i) 
a hydrazine and a reducing sugar group. 
34. A method according to claim 1, 19, 21, 22, 31 or 
32 wherein the reaction between the distinctive reactive 
substituent and the specifically reactive group is a non 
competitive reaction which does not involve other 
functional groups of the protein or is a competitive 
reaction which is controlled to provide substantially 
selective reaction between the specifically reactive 
group and distinctive reactive substituent relative to the 
reaction of either of the specifically reactive group and 
the distinctive reactive substituent with other functional 
groups of the protein. 
35. A method for preparing a protein-bioactive agent 
composition, comprising: 
binding a nucleophile and a bioactive agent to form 
an intermediate, said nucleophile being an amino 
acid, amine or alcohol having an amine or alcohol 
group and a side chain with a reactive substituent, 
and said bioactive agent having at least one specifi 
cally reactive group that is reactive toward the 
reactive substituent of the nucleophile, and the 
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binding being between the reactive substituent and 
the specifically reactive group; and 
coupling the intermediate and a protein having a 
C-terminus amino acid with the C-terminus as a 
carboxylic acid having a carbonyl group, and an 5 
amino acid penultimate to the C-terminus amino 
acid in a medium at acidic or basic pH and in the 
presence of an exopeptidase enzyme to form the 
protein-bioactive agent composition, the coupling 
being between the amine or alcohol group of the 
nucleophile residue of the intermediate and the 
C-terminus carboxylic acid group of the protein or 
the carbonyl group of the amino acid penultimate 
to the C-terminus of the protein; and 
wherein the protein-bioactive agent composition is a 
straight chain of the protein, nucleophile and bioactive 
agent bonded together, and only two sites on the nu 
cleophile as well as only one site on each of the protein 
and bioactive agent are chain binding sites. 
36. A method for preparing a protein-bioactive agent 
composition, comprising: 
combining a bioactive agent and a linker arm to form 
covalently bound combination, said bioactive 
agent having at least one combining group, said 
linker arm being a flexible or semi-flexible chain 
having a specifically reactive group that is or is 
rendered non-reactive toward the combining 
group and another reactive group that is reactive 
toward the combining group of the bioactive 
agent, and the combining being between the com 
bining group and the reactive group; 
binding a nucleophile and the combination to form an 
intermediate, said nucleophile being an amino acid, 
amine or alcohol having an amine or alcohol group 
and a side chain with a reactive substituent that is 35 
reactive toward the specifically reactive group of 
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the combination, and the binding being between 
the reactive substituent and the specifically reac 
tive group; and 
coupling the intermediate and a protein having a 
C-terminus amino acid with the C-terminus as a 
carboxylic acid having a carbonyl group, and an 
amino acid penultimate to the C-terminus amino 
acid in a medium at acidic or basic pH and in the 
presence of an exopeptidase enzyme to form the 
protein-bioactive agent composition, the coupling 
being between the amine or alcohol group of the 
nucleophile and the C-terminus carboxylic acid 
group of the protein or the carbonyl group of the 
amino acid penultimate to the C-terminus of the 
protein; and 
wherein the protein-bioactive agent composition is a 
straight chain of the protein, nucleophile, linker and 
bioactive agent bonded together, and only two sites on 
each of the nucleophile and linker as well as only one 
site on each of the protein and bioactive agent are chain binding sites. 
37. A protein augmented by a bioactive agent pre 
pared by a method according to claim 31, 32, 35, or 36. 
38. A method according to claim 1, 2, 19, 20, 22, 23, 
32 or 36 wherein the linker arm chain is a polymer or 
oligomer of amide, ester, carbonate, urethane, ether, 
glycidyl, olefin or hydrocarbon groups, is an aliphatic 
group of from about 2 to 20 atoms, or is an aromatic 
group of from about 1 to 5 rings. 
39. A method according to claim 21, 22, 23, 24, 31, 32, 
35 or 36 wherein the coupling conditions are basic and 
the nucleophile is an amino acid or amine. 
40. A method according to claim 21, 22, 23, 24, 31, 32. 
35 or 36 wherein the coupling conditions are acidic and 
the nucleophile is an alcohol. 
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